Media coverage
9
Media coverage
Title Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia Media name/outlet India Pharma News Country/Territory India Date 15/11/17 Persons Lewis Silverman Title Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia Media name/outlet Pettinga Financial Advisors Country/Territory United States Date 15/11/17 URL markets.pettinga.com/pettinga/news/read?GUID=35297000 Persons Lewis Silverman Title Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia Media name/outlet SPi World News Country/Territory United Kingdom Date 15/11/17 URL www.sectorpublishingintelligence.co.uk/news/1843185/onconova+therapeutics+announces+publication+of+results+from+phase+12+study+of+rigosertib+in+patients+with+myelodysplastic+syndromes+mds+and+mds+progressed+to+acute+myeloid+leukemia Persons Lewis Silverman Title Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia Media name/outlet Nasdaq Country/Territory United States Date 15/11/17 URL www.nasdaq.com/press-release/onconova-therapeutics-announces-publication-of-results-from-phase-12-study-of-rigosertib-in-20171115-00627 Persons Lewis Silverman Title Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia Media name/outlet Spoke.com Country/Territory United States Date 15/11/17 URL www.spoke.com/press_releases/5a0c4e3330336b6dc00008ad Persons Lewis Silverman Title Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia Media name/outlet PrimeNewswire (Top News) Country/Territory United States Date 15/11/17 Persons Lewis Silverman Title Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia Media name/outlet GlobeNewswire Country/Territory United States Date 15/11/17 URL globenewswire.com/news-release/2017/11/15/1193510/0/en/Onconova-Therapeutics-Announces-Publication-of-Results-from-Phase-1-2-Study-of-Rigosertib-in-Patients-with-Myelodysplastic-Syndromes-MDS-and-MDS-Progressed-to-Acute-Myeloid-Leukemi.html?f=22&fvtc=7 Persons Lewis Silverman Title Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia Media name/outlet Daily Times Leader Country/Territory United States Date 15/11/17 URL business.dailytimesleader.com/dailytimesleader/news/read?GUID=35297000 Persons Lewis Silverman Title Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia Media name/outlet BizWire Express Country/Territory India Date 15/11/17 URL www.bizwireexpress.com/showstoryGNW.php?storyid=206590 Persons Lewis Silverman